Loading...
•
Jun 30, 2023
InspireMD Q2 2023 Earnings Report
InspireMD's Q2 2023 earnings reflected a revenue increase and advancements in clinical trials and financing.
Key Takeaways
InspireMD reported a 7.7% increase in revenue to $1.649 million for Q2 2023, driven by a 9.6% increase in CGuard EPS sales. The company completed a private placement for up to $113.6 million and enrollment in the C-Guardians US IDE trial.
Completed a transformational private placement for up to $113.6 million, including $42.2 million upfront.
Finished enrollment in the C-Guardians US IDE trial, with primary and secondary endpoints expected to be announced in H2 2024.
CGuard EPS revenue increased by nearly 10% over Q2 2022, reaching $1.6 million.
Gross profit increased by 14.0% to $491,000 from $431,000 in Q2 2022.
Revenue by Segment
Forward Guidance
InspireMD anticipates potential regulatory approval and launch of the CGuard stent system in the U.S., initiating regulatory pathways for new advanced indications for CGuard, and developing new products, while at the same time continuing to grow its business in approved markets outside of the United States.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...